/NXTC
NXTC Stock - NextCure, Inc.
Healthcare|BiotechnologyNASDAQ
$11.38+6.36%
+$0.68 (+6.36%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.58
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+31.8%upside
Target: $15.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NXTC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.27 – $11.49
TARGET (TP)$15.00
STOP LOSS$10.47
RISK/REWARD1:4.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.54
52W High$15.74
52W Low$2.69
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $22.38M |
| Gross Profit | N/A | N/A | N/A | N/A | $-24,176,000 |
| Gross Margin | N/A | N/A | N/A | N/A | -108.0% |
| Operating Income | $-59,748,000 | $-67,637,000 | $-75,909,000 | $-70,765,000 | $-41,225,000 |
| Net Income | $-55,654,000 | $-62,723,000 | $-74,733,000 | $-69,389,000 | $-36,603,000 |
| Net Margin | N/A | N/A | N/A | N/A | -163.6% |
| EPS | $-23.88 | $-27.04 | $-32.32 | $-30.15 | $-15.95 |
Company Overview
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$18
Average Target
↑ 58.2% Upside
Now
$18
Low
$18
Average
$18
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 7th 2025 | Ladenburg Thalmann | Upgrade | Buy | $18 |
| November 4th 2022 | Ladenburg Thalmann | Downgrade | Neutral | - |
Earnings History & Surprises
NXTCBeat Rate
50%
Last 18 quarters
Avg Surprise
-12.4%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-3.22
Q4 2025
EPS Surprise History
Q1 24
+3.7%
$-0.52vs$-0.54
Q2 24
-35.6%
$-0.61vs$-0.45
Q3 24
-52.8%
$-0.55vs$-0.36
Q4 24
-17.1%
$-0.41vs$-0.35
Q1 25
-20.6%
$-0.41vs$-0.34
Q2 25
+2.5%
$-4.68vs$-4.80
Q3 25
-144.4%
$-11.29vs$-4.62
Q4 25
+20.7%
$-3.22vs$-4.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-2.26 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-4.06 | $-3.22 | +20.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-4.62 | $-11.29 | -144.4% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-4.80 | $-4.68 | +2.5% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.34 | $-0.41 | -20.6% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.35 | $-0.41 | -17.1% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.36 | $-0.55 | -52.8% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.45 | $-0.61 | -35.6% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.54 | $-0.52 | +3.7% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.64 | $-0.51 | +20.3% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.60 | $-0.64 | -6.7% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.64 | $-0.58 | +9.4% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-0.65 | $-0.62 | +4.6% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.60 | $-0.68 | -13.3% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.73 | $-0.65 | +11.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.68 | $-0.74 | -8.8% | ✗ MISS |
Q1 2022 | Mar 3, 2022 | $-0.67 | $-0.61 | +9.0% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.67 | $-0.65 | +3.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.60 | $-0.65 | -8.3% | ✗ MISS |
Latest News
NextCure Files For Offering Of Up To 2.52M Common Shares By Selling Stockholders
➖ NeutralBenzinga•Nov 26, 2025, 09:05 PM
NextCure shares are trading higher after the company announced a $21.5 million private placement.
📈 PositiveBenzinga•Nov 12, 2025, 01:05 PM
NextCure Announces $21.5 Private Placement For Purchase And Sale Of 2,523,477 Shares At $8.52/Share
➖ NeutralBenzinga•Nov 12, 2025, 01:05 PM
Ladenburg Thalmann Upgrades NextCure to Buy, Announces $18 Price Target
📈 PositiveBenzinga•Nov 7, 2025, 12:49 PM
NextCure Q3 EPS $(3.22) Beats $(3.98) Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:52 PM
NextCure shares are trading higher after the company announced it dosed first U.S. patient with SIM0505 in global phase 1 cancer trial.
📈 PositiveBenzinga•Oct 16, 2025, 05:24 PM
NextCure Doses First U.S. Patient With SIM0505 In Global Phase 1 Cancer Trial; Targets Proof-Of-Concept Data By 1H 2026
📈 PositiveBenzinga•Oct 16, 2025, 12:09 PM
Frequently Asked Questions about NXTC
What is NXTC's current stock price?
NextCure, Inc. (NXTC) is currently trading at $11.38 per share. The stock has moved +6.36% today.
What is the analyst price target for NXTC?
The average analyst price target for NXTC is $15.00, based on 1 analyst.
What sector is NextCure, Inc. in?
NextCure, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NXTC's market cap?
NextCure, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does NXTC pay dividends?
No, NextCure, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
BOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
INTS
Intensity Therapeutics, Inc.
$0.41
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
PLUR
Pluri Inc.
$3.40
Mkt Cap: $0.0B
PSTV
Plus Therapeutics, Inc.
$0.57
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
VRCA
Verrica Pharmaceuticals Inc.
$7.82
Mkt Cap: $0.1B
Explore stocks similar to NXTC for comparison